Fundraising Fox
Axonis Therapeutics
Boston, US · Founded 2019 · Delaware corporation · 27 employees on LinkedIn · 15 known investors
Find your way into Axonis Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Lu Han to introduce you to Shane V. Hegarty
You →Lu · together at Axonis Therapeutics →Shane
Ask Jamie Chen to introduce you to Jeff Imbaro
You →Jamie · together at Elevian →Jeff
Sign up to find every way you can get introduced to Axonis Therapeutics
- Your email: who you already know at Axonis Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Axonis Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain. It translates discoveries from Boston Children's Hospital, Harvard and Laval University into central nervous system therapies.
Founders & leadership
Axonis Therapeutics was founded in 2019 by Shane V. Hegarty.
Board
Investors · 15
How we know: the company's own site · a partner's Signal profile · the VCSheet dataset · sofinnova.com · Not right? Tell us
How we know: the company's own site · the VCSheet dataset · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: funding news · the VCSheet dataset · Not right? Tell us
How we know: Iaso Ventures's portfolio page · Not right? Tell us
How we know: Lumira Ventures's portfolio page · funding news · Not right? Tell us
How we know: SCI Ventures's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$46M disclosed across 1 round · 2024
▶$46MraisedNov 2024 · 19 investors · BiotechnologyRule 506(b)
- Donald Manning, M.D., Ph.DExecutive Officer
- Jeffrey ImbaroExecutive Officer
- Corey . GoodmanDirector
- Brock ReeveDirector
- Shane HegartyExecutive Officer
- Joanna StanickaExecutive Officer, Director
- Jonathan LeffDirector
- Raymond J. KelleherDirector
- Offering amount
- $115M
- Amount sold
- $46M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Axonis Therapeutics went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Axonis Therapeutics.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $299.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $335.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $298.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $330.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Axonis Therapeutics do?
- Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain. It translates discoveries from Boston Children's Hospital, Harvard and Laval University into central nervous system therapies.
- Who founded Axonis Therapeutics?
- Axonis Therapeutics was founded by Shane V. Hegarty in 2019.
- Who are Axonis Therapeutics's investors?
- Axonis Therapeutics's investors include Sofinnova Ventures, venBio Partners, MRL Ventures Fund, Civilization Ventures Management, Llc, Creative Destruction Lab (CDL), Hatteras Venture Partners, Iaso Ventures, Lumira Ventures and 7 more.
- How much funding has Axonis Therapeutics raised?
- Axonis Therapeutics has disclosed $46M raised across 1 round.
- Where is Axonis Therapeutics headquartered?
- Axonis Therapeutics is headquartered in Boston, US.